- Home
- VTYX vs EDF Comparison
VTYX vs EDF Comparison
Compare VTYX & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- EDF
- Stock Information
- Founded
- VTYX 2018
- EDF 2010
- Country
- VTYX United States
- EDF United States
- Employees
- VTYX N/A
- EDF N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- EDF Investment Managers
- Sector
- VTYX Health Care
- EDF Finance
- Exchange
- VTYX Nasdaq
- EDF Nasdaq
- Market Cap
- VTYX 154.9M
- EDF 148.8M
- IPO Year
- VTYX 2021
- EDF N/A
- Fundamental
- Price
- VTYX $1.17
- EDF $4.88
- Analyst Decision
- VTYX Buy
- EDF
- Analyst Count
- VTYX 4
- EDF 0
- Target Price
- VTYX $11.33
- EDF N/A
- AVG Volume (30 Days)
- VTYX 965.2K
- EDF 160.6K
- Earning Date
- VTYX 05-16-2025
- EDF 01-01-0001
- Dividend Yield
- VTYX N/A
- EDF 13.14%
- EPS Growth
- VTYX N/A
- EDF N/A
- EPS
- VTYX N/A
- EDF N/A
- Revenue
- VTYX N/A
- EDF N/A
- Revenue This Year
- VTYX N/A
- EDF N/A
- Revenue Next Year
- VTYX N/A
- EDF N/A
- P/E Ratio
- VTYX N/A
- EDF N/A
- Revenue Growth
- VTYX N/A
- EDF N/A
- 52 Week Low
- VTYX $0.78
- EDF $3.51
- 52 Week High
- VTYX $5.66
- EDF $5.50
- Technical
- Relative Strength Index (RSI)
- VTYX 46.01
- EDF 52.37
- Support Level
- VTYX $1.05
- EDF $4.81
- Resistance Level
- VTYX $1.48
- EDF $5.03
- Average True Range (ATR)
- VTYX 0.11
- EDF 0.11
- MACD
- VTYX 0.01
- EDF 0.02
- Stochastic Oscillator
- VTYX 27.91
- EDF 64.29
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.